Lineage Cell Therapeutics Inc
AMEX:LCTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
L
|
Lineage Cell Therapeutics Inc
AMEX:LCTX
|
US |
|
C
|
China Pacific Insurance Group Co Ltd
F:75C
|
CN |
|
I
|
Infineon Technologies AG
SWB:IFX
|
DE |
|
Health Catalyst Inc
F:2YP
|
US |
|
D
|
Dai-ichi Life Holdings Inc
OTC:DLICY
|
JP |
|
N
|
Nordstrom Inc
SWB:NRD
|
US |
|
C
|
Capitol Federal Financial Inc
F:CFW
|
US |
|
Edgewell Personal Care Co
NYSE:EPC
|
US |
|
T
|
Telstra Group Ltd
F:5KB
|
AU |
|
T
|
Talanx AG
DUS:TLX
|
DE |
|
N
|
National Vision Holdings Inc
F:7NV
|
US |
|
U
|
UBE Corp
DUS:UBE
|
JP |
|
Logan Energy Corp
F:R76
|
CA |
|
C
|
China Life Insurance Co Ltd
F:CLF
|
CN |
|
Pennon Group PLC
F:3PN
|
UK |
|
D
|
Deutsche Boerse AG
F:63DA
|
DE |
Wall St Price Targets
LCTX Price Targets Summary
Lineage Cell Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for LCTX is 5.61 USD with a low forecast of 3.03 USD and a high forecast of 9.45 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is LCTX's stock price target?
Price Target
5.61
USD
According to Wall Street analysts, the average 1-year price target for LCTX is 5.61 USD with a low forecast of 3.03 USD and a high forecast of 9.45 USD.
What is the Revenue forecast for Lineage Cell Therapeutics Inc?
Projected CAGR
74%
Over the last 14 years, the compound annual growth rate for Revenue has been 9%. The projected CAGR for the next 8 years is 74%.
What is the Gross Profit forecast for Lineage Cell Therapeutics Inc?
Projected CAGR
74%
Over the last 14 years, the compound annual growth rate for Gross Profit has been 9%. The projected CAGR for the next 8 years is 74%.
